Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nat Rev Cancer. 2005 Jun;5(6):468-79.

Antisense therapy for cancer.

Author information

  • 1The Prostate Centre at Vancouver General Hospital, and Division of Urology, University of British Columbia D9, Canada, V5Z 355. gleave@interchange.ubc.ca

Abstract

Improved understanding of the molecular mechanisms that mediate cancer progression and therapeutic resistance has identified many therapeutic gene targets that regulate apoptosis, proliferation and cell signalling. Antisense oligonucleotides offer one approach to target genes involved in cancer progression, especially those that are not amenable to small-molecule or antibody inhibition. Better chemical modifications of antisense oligonucleotides increase resistance to nuclease digestion, prolong tissue half-lives and improve scheduling. Indeed, recent clinical trials confirm the ability of this class of drugs to significantly suppress target-gene expression. The current status and future directions of several antisense drugs that have potential clinical use in cancer are reviewed.

PMID:
15905854
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk